Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

hose detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

(Tables Attached)

The following tables present Endo's unaudited net sales for the three months ended March 31, 2009 and March 31, 2008:

                            Endo Pharmaceuticals Holdings Inc.
                                 Net Sales (unaudited)
                                    (in thousands)


                                                    Three Months Ended
                                                         March 31,

                                                    2009             2008

    LIDODERM(R)                                  $171,636         $180,524
    OPANA(R) ER AND OPANA(R)                       52,765           40,283
    Percocet(R)                                    33,690           31,800
    FROVA(R)                                       12,292           14,055
    Voltaren(R) Gel                                12,319                -
    Other Brands *                                 10,205            1,816

    Total Brands                                 $292,907      
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... R.I. (PRWEB) May 04, 2015 Johnson & ... $40 million engineering and science academic center on Wednesday, April ... the ground for land made available by the re-alignment of ... the corner of Friendship and Chestnut streets in Providence, is ... built on a parcel of land the university purchased in ...
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The American ... critical state policy reports which identify gaps in coverage ... “After ATA issued the State Telemedicine Gaps Reports last ... how their laws and regulations impact healthcare delivery in ... a result of state actions across the nation, ATA ...
(Date:5/4/2015)... Baptist Medical Center Jacksonville has received ... The Guidelines®-Stroke Gold Plus Quality Achievement Award along ... recognizes the hospital’s commitment and success in ensuring ... according to nationally recognized, research-based guidelines based on ... Gold Plus Quality Achievement Award, hospitals must achieve ...
(Date:5/4/2015)... Greifensee, Switzerland (PRWEB) May 04, 2015 ... entitled “ The Importance of Data Integrity in ... Bob McDowall as guest presenter. This webinar will ... EDT (15:00 GMT). , Data integrity is a ... information submitted to regulatory agencies. However, in recent ...
Breaking Medicine News(10 mins):Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2
... Results Capture Perspectives of People Living with Rheumatoid, ... a Span of 30 Years, HORSHAM, Pa., ... challenges cited by people diagnosed with,rheumatoid arthritis (RA), ... groundbreaking parallel surveys. According to the GeneRAtions(TM),surveys -- ...
... Budget Challenge, SACRAMENTO, Calif., July 29 ... organization Next 10 has just released,a newly updated ... voters,can try their hand at dealing with the ... re-released 2008 Budget Challenge, an online,interactive educational game, ...
... BEDFORD, Mass., July 29 Insulet Corporation,(Nasdaq: PODD ... OmniPod(R),Insulin Management System, announced plans to release its financial ... 2008 after the close of,the financial markets., Insulet ... Eastern Time on,Tuesday, August 12, 2008 to discuss its ...
... American Media, Inc. (AMI), the,leading publisher of celebrity ... provided dial-in information for the conference call it,plans to ... for the holders of,the senior subordinated notes of its ... conference call will be to update,noteholders with respect to ...
... Infants Died in 2005, WHITE PLAINS, N.Y., July ... for a growing proportion of infant deaths,according to new ... (NCHS)., Babies who died of preterm-related causes accounted ... 34.6 percent in 2000, according to "Infant,Mortality Statistics from ...
... cancer screening program in Norway and an approach to ... are equally sensitive for detecting cancer, researchers report in ... of the National Cancer Institute . But the recall ... Breast cancer screening in the United States is usually ...
Cached Medicine News:Health News:New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through 'Generations' 2Health News:New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through 'Generations' 3Health News:New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through 'Generations' 4Health News:New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through 'Generations' 5Health News:As Budget Stalemate Wears On - Voters Can Set Their Own Priorities 2Health News:Insulet Corporation to Report Second Quarter 2008 Financial Results on Tuesday, August 12, 2008 2Health News:Preterm Birth Contributes to Growing Number of Infant Deaths 2Health News:2 different breast cancer screening strategies are equally effective 2
(Date:5/4/2015)... FRAMINGHAM, Mass. , May 4, 2015   HeartWare ... of less invasive, miniaturized circulatory support technologies that are revolutionizing ... and CEO, Doug Godshall , is scheduled to present ... Conference in Las Vegas on Thursday, ... The live webcast of the Company,s presentation at ...
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... 27 Due to rising patient responsibility for ... state laws requiring disclosure of information on hospital charges, ... estimates for healthcare services. Competitive hospitals also realize they ... accountability to key stakeholders, protect against compliance risks, focus ...
... , , ... 280,000 external defibrillators used worldwide in health care facilities, public places, or in the home ... Drug Administration warned today. , , , ... , , , ...
Cached Medicine Technology:Craneware Shares Patient Estimation Revenue Integrity Insights 2Craneware Shares Patient Estimation Revenue Integrity Insights 3Craneware Shares Patient Estimation Revenue Integrity Insights 4FDA Warns Users About Faulty Components in 14 External Defibrillator Models 2FDA Warns Users About Faulty Components in 14 External Defibrillator Models 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: